登录    
  
首页 > 期刊论文 > 论文摘要
表皮生长因子受体基因CA简单重复序列多态性与晚期小细胞肺癌患者表皮生长因子受体酪氨酸激酶抑制剂临床疗效间的关系
         
Correlation of CA-simple sequence repeat polymorphism of epidermal growth factor receptor gene with clinical outcome of patients with advanced non-small cell lung cancer after treatment with epidermal growth factor receptor tyrosine kinase inhibitors

摘    要
目的:研究表皮生长因子受体(epidermal growth factor receptor,EGFR)基因第1内含子区CA简单重复序列(simple sequence repeat,SSR)多态性与晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者应用表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitors,EGFR-TKIs)治疗的临床疗效间的关系。方法:观察101例晚期NSCLC患者使用EGFR-TKIs的临床疗效及生存情况,通过对患者EGFR-TKIs治疗前外周血进行EGFR基因第1内含子的PCR扩增,并对PCR扩增产物直接进行序列测定,分析CA-SSR多态性与EGFR-TKIs治疗的临床疗效和患者生存情况间的关系。结果:EGFR-TKIs治疗后,24例(23.8%)患者部分缓解(partial response,PR),46例(45.5%)患者为疾病稳定(stable disease,SD),临床受益(PR+SD)患者为70例(69.3%)。腺癌和女性患者的中位生存期(median survival time,MST)较非腺癌和男性患者明显延长(P<0.05)。CA-SSR出现频率最多的CA等位基因为(CA)20[68.7%(68/99)],短CA-SSR组患者经EGFR-TKIs治疗后的无进展生存(progression-free survival,PFS)时间比长CA-SSR患者明显延长(P=0.039);短CA-SSR组MST为15.7个月,长CA-SSR组MST为14.4个月,组间差异无统计学意义(P=0.691)。结论:EGFR-TKIs治疗可明显延长腺癌、女性NSCLC患者的MST和短CA-SSR患者的PFS。
标    签 癌,非小细胞肺   受体,表皮生长因子   多态现象,单核苷酸   表皮生长因子受体酪氨酸激酶抑制剂   Carcinoma,non-small cell lung   Receptor,epidermal growth factor   Polymorphism,single nucleotide   Epidermal growth factor receptor tyrosine kinase inhibitor  
 
Abstract
Objective:To investigate the correlation of CA-simple sequence repeat(SSR) polymorphism of epidermal growth factor receptor(EGFR) gene with the clinical outcome of patients with advanced non-small cell lung cancer(NSCLC) after treatment with epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs).Methods:The clinical outcome and the survival of 101 patients with advanced NSCLC after treatment with EGFR-TKIs were measured.CA-SSR polymorphisim of EGFR intron 1 from peripheral blood cells of NSCLC patients was detected by PCR and direct DNA sequencing.The correlations of CA-SSR polymorphisim with the clinical outcome and the survival of NSCLC patients after treatment with EGFR-TKIs were analyzed.Results:Twenty-four patients reached a partial response(23.8%),46 patients reached a stable disease(45.5%),and 70 patients reached a clinical benefit(69.3%).Median survival time(MST) in female or adenocarcinoma patients was longer than that in male or non-adenocarcinoma patients(P<0.05).Allele(CA)20 was the most frequent allele(68.7%,68/99) in CA-SSR.Progression-free survival(PFS) in patients with short CA-SSR was longer than that in patients with long CA-SSR(P=0.039).The MSTs of patients with short CA-SSR and long CA-SSR were 15.7 and 14.4 months,respectively,and the difference in MST was not significant(P=0.691).Conclusion:The MST of female or adenocarcinoma patients with NSCLC as well as the PSF of patients with short CA-SSR can be prolonged after treatment with EGFR-TKIs.

中图分类号 R734.2   DOI 10.3781/j.issn.1000-7431.2011.07.011

 
  购买该论文  中国光学期刊网论文下载说明
      


所属栏目 临床研究

基金项目 上海市卫生局青年科研项目(编号:2007Y51)

收稿日期 2011/3/23

修改稿日期 2011/6/10

网络出版日期

作者单位点击查看


引用该论文: ZHOU Song-wen,XU Qing-hua,ZHANG Jie,DENG Qin-fang,REN Sheng-xiang,ZHOU Cai-cun. Correlation of CA-simple sequence repeat polymorphism of epidermal growth factor receptor gene with clinical outcome of patients with advanced non-small cell lung cancer after treatment with epidermal growth factor receptor tyrosine kinase inhibitors[J]. Tumor, 2011, 31(7): 633~637
周崧雯,徐清华,张颉,邓沁芳,任胜祥,周彩存. 表皮生长因子受体基因CA简单重复序列多态性与晚期小细胞肺癌患者表皮生长因子受体酪氨酸激酶抑制剂临床疗效间的关系[J]. 肿瘤, 2011, 31(7): 633~637


论文评价
共有人对该论文发表了看法,其中:
人认为该论文很差
人认为该论文较差
人认为该论文一般
人认为该论文较好
人认为该论文很好
分享论文
分享到新浪微博 分享到腾讯微博 分享到人人网 分享到 Google Reader 分享到百度搜藏分享到Twitter

参考文献
【1】CARNEY D N. Lung cancer-time to move on from chemotherapy[J]. N Engl J Med, 2002, 346(2):126-128.
 
【2】CARNEY D N. Lung cancer-time to move on from chemotherapy[J]. N Engl J Med, 2002, 346(2):126-128.
 
【3】KIM E S, HIRSH V, MOK T, et al. Gefitinib versus docetaxel in previously treated non-small cell lung cancer (INTEREST):a randomised phase Ⅲ trial[J]. Lancet, 2008, 372(9652):1809-1818.
 
【4】KIM E S, HIRSH V, MOK T, et al. Gefitinib versus docetaxel in previously treated non-small cell lung cancer (INTEREST):a randomised phase Ⅲ trial[J]. Lancet, 2008, 372(9652):1809-1818.
 
【5】SHEPHERD F A, RODRIGUES PEREIRA J, CIULEANU T, et al. Erlotinib in previously treated non-small cell lung cancer[J]. N Engl J Med, 2005, 353(2):123-132.
 
【6】SHEPHERD F A, RODRIGUES PEREIRA J, CIULEANU T, et al. Erlotinib in previously treated non-small cell lung cancer[J]. N Engl J Med, 2005, 353(2):123-132.
 
【7】TSAO M S, SAKURADA A, CUTZ J C, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome[J]. N Engl J Med, 2005, 353(2):133-144.
 
【8】TSAO M S, SAKURADA A, CUTZ J C, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome[J]. N Engl J Med, 2005, 353(2):133-144.
 
【9】GEBHARDT F, ZÄNKER K S, BRANDT B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1[J]. J Biol Chem, 1999, 274(19):13176-13180.
 
【10】GEBHARDT F, ZÄNKER K S, BRANDT B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1[J]. J Biol Chem, 1999, 274(19):13176-13180.
 
【11】DUBEY S, STEPHENSON P, LEVY DE, et al. EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer[J]. J Thorac Oncol, 2006, 1(5):406-412.
 
【12】DUBEY S, STEPHENSON P, LEVY DE, et al. EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer[J]. J Thorac Oncol, 2006, 1(5):406-412.
 
【13】TISEO M, CAPELLETTI M, D E PALMA G, et al. Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer[J]. J Thorac Oncol, 2008, 3(10):1104-1111.
 
【14】TISEO M, CAPELLETTI M, D E PALMA G, et al. Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer[J]. J Thorac Oncol, 2008, 3(10):1104-1111.
 
【15】HAN S W, JEON Y K, LEE KH, et al. Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small cell lung cancer[J]. Pharmacogenet Genomics, 2007, 17(5):313-319.
 
【16】HAN S W, JEON Y K, LEE KH, et al. Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small cell lung cancer[J]. Pharmacogenet Genomics, 2007, 17(5):313-319.
 
【17】ZHU C Q, DA CUNHA SANTOS G, DING K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21[J]. J Clin Oncol, 2008, 26(26):4268-4275.
 
【18】ZHU C Q, DA CUNHA SANTOS G, DING K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21[J]. J Clin Oncol, 2008, 26(26):4268-4275.
 
【19】SEQUIST L V, MARTINS R G, SPIGEL D, et al. First-line gefitinib in patients with advanced non-small cell lung cancer harboring somatic EGFR mutations[J]. J Clin Oncol, 2008, 26(15):2442-2449.
 
【20】SEQUIST L V, MARTINS R G, SPIGEL D, et al. First-line gefitinib in patients with advanced non-small cell lung cancer harboring somatic EGFR mutations[J]. J Clin Oncol, 2008, 26(15):2442-2449.
 
【21】王理扬, 黄媚娟, 李 伦, 等. 非小细胞肺癌组织化疗前后表皮生长因子受体基因的突变[J]. 肿瘤, 2011, 31(6):517-521.
 
【22】王理扬, 黄媚娟, 李 伦, 等. 非小细胞肺癌组织化疗前后表皮生长因子受体基因的突变[J]. 肿瘤, 2011, 31(6):517-521.
 
【23】黄逸生, 杨衿记, 黄玉娟, 等. 厄洛替尼二、三线治疗晚期非小细胞肺癌的临床研究[J]. 中国肺癌杂志, 2009, 12(5):412-416
 
【24】黄逸生, 杨衿记, 黄玉娟, 等. 厄洛替尼二、三线治疗晚期非小细胞肺癌的临床研究[J]. 中国肺癌杂志, 2009, 12(5):412-416
 
【25】LIU W, INNOCENTI F, CHEN P, et al. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism[J]. Clin Cancer Res, 2003, 9(3):1009-1012.
 
【26】LIU W, INNOCENTI F, CHEN P, et al. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism[J]. Clin Cancer Res, 2003, 9(3):1009-1012.
 
【27】LEE S J, KIM K M, CHAE M H, et al. No association between dinucleotide repeat polymorphism in intron 1 of the epidermal growth factor receptor gene EGFR and risk of lung cancer[J]. Cancer Genet Cytogenet, 2007, 172(1):29-32.
 
【28】LEE S J, KIM K M, CHAE M H, et al. No association between dinucleotide repeat polymorphism in intron 1 of the epidermal growth factor receptor gene EGFR and risk of lung cancer[J]. Cancer Genet Cytogenet, 2007, 172(1):29-32.
 
【29】AMADOR M L, OPPENHEIMER D, PEREA S, et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors[J]. Cancer Res, 2004, 64(24):9139-9143.
 
【30】AMADOR M L, OPPENHEIMER D, PEREA S, et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors[J]. Cancer Res, 2004, 64(24):9139-9143.
 
【31】SUEOKA-ARAGANE N, IMAI K, KOMIYA K, et al. Exon 19 of EGFR mutation in relation to the CA-repeat polymorphism in intron 1[J]. Cancer Sci, 2008, 99(6):1180-1187.
 
【32】SUEOKA-ARAGANE N, IMAI K, KOMIYA K, et al. Exon 19 of EGFR mutation in relation to the CA-repeat polymorphism in intron 1[J]. Cancer Sci, 2008, 99(6):1180-1187.
 
相关信息
   标题 相关频次
 靶向肿瘤新生血管的顺磁性纳米脂质体在MRI诊断肺癌中的研究
 6
 厄洛替尼治疗晚期非小细胞肺癌的临床研究
 6
 人肺腺癌吉非替尼耐药细胞株中微小RNA的表达谱
 6
 人肺腺癌细胞株A549和A549/DDP的比较蛋白质组学研究
 6
 首剂负荷量伊班膦酸钠治疗肺癌转移性骨痛的疗效和安全性分析
 6
 胸苷酸合酶基因变数串联重复多态性与培美曲塞治疗晚期非小细胞肺癌疗效相关性分析
 5
 血管内皮生长因子C过表达或抑制表达对人小细胞肺癌NCI-H446细胞生物学行为的影响
 5
 GRIM-19基因对肺腺癌耐药细胞株A549/DDP药物敏感性及相关基因表达的影响
 4
 Ⅰ~Ⅲ期肺腺癌组织中EGFR基因突变与ERCC1和RRM1蛋白表达的关系
 4
 Ⅳ型胶原对耐顺铂人肺腺癌细胞化疗诱导凋亡的影响
 4
 8q24 rs13281615单核苷酸多态性与乳腺癌发病风险的Meta分析
 4
 cRGD-氧化铁纳米粒的构建及应用于核磁共振成像诊断中的动物研究
 4
 ERCC1、RRM1和BRCA1在非小细胞肺癌中的表达及预后意义
 4
 H2O2氧化刺激对紫杉醇耐药和敏感肺癌细胞的不同影响
 4
 H101溶瘤腺病毒联合长春瑞滨/顺铂一线治疗晚期非小细胞肺癌
 4
 Luffin-β靶向融合免疫毒素的构建、表达及对非小细胞肺癌的抑制作用
 4
 STI 571增强非小细胞肺癌对顺铂的敏感性
 4
 贝伐单抗联合紫杉醇/卡铂治疗晚期非鳞状细胞型非小细胞肺癌44例临床分析
 4
 表皮生长因子受体信号通路与卵巢癌耐药细胞株SKOV3/DDP相关性的研究
 4
 初治晚期无症状脑转移非小细胞肺癌患者全脑放疗的时序探讨
 4
 单药培美曲塞二线治疗晚期非小细胞肺癌的疗效观察
 4
 非小细胞肺癌患者EGFR基因突变状态影响因素的临床分析
 4
 非小细胞肺癌组织中血管内皮生长因子表达与树突状细胞分布的关系
 4
 高海拔地区老年非小细胞肺癌患者接受全电视胸腔镜下肺叶切除的安全性和预后分析
 4
 化疗序贯厄洛替尼治疗二线厄洛替尼耐药晚期非小细胞肺癌的临床疗效和安全性
 4
 吉非替尼耐药细胞株的筛选和基因谱表达研究
 4
 扩增阻滞突变系统法检测非小细胞肺癌微小标本表皮生长因子受体突变
 4
 硫酸基转移酶1E1基因单核苷酸多态性联合吸烟与肺癌易感性的关系
 4
 培美曲塞治疗非小细胞肺癌无症状脑转移临床分析
 4
 上皮-间质转化和胰岛素样生长因子Ⅰ型受体在非小细胞肺癌EGFR-TKIs获得性耐药中的作用
 4

  热点专题


关于我们  |   联系我们  |   广告投放  |   《肿瘤》杂志社版权所有 《肿瘤》杂志社   © 中国 上海 2014.3
沪ICP备15036656号-2